Lamuran

Quick links to important sections

Lamuran

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lamuran

Property Description
Active ingredient Raubasine (Ajmalicine)
Form Oral Tablet (Film-Coated)
Pharmacological class alpha1-Adrenergic Antagonist
General purpose Supports Circulation / Regulates Vascular Tone
Origin Phytochemical (Indole Alkaloid)

What is the Core Composition and Type of Lamuran?

Lamuran is a defined pharmaceutical preparation characterized by its single active component, Raubasine, which is chemically recognized as Ajmalicine. The active ingredient is classified as a monoterpenoid indole alkaloid, a complex organic nitrogen-containing compound naturally derived from plant sources, such as specific species of the Rauvolfia genus, placing it in the category of agents with a phytochemical origin. This classification is characterized by its structural properties as a unique alpha-yohimbine isomer. The preparation is consistently manufactured for oral intake, typically presented as a single product in the form of film-coated tablets or a similar oral solid dosage form, and is generally designated for adult use as a prescription drug.

How is Lamuran Pharmacologically Classified?

Lamuran's classification reflects its primary action as both a peripheral vasodilator and a targeted cerebrovascular agent. Its functional core is its mechanism as a selective alpha1-Adrenergic Antagonist, which blocks receptors that cause blood vessels to tighten. This action facilitates cerebral and peripheral blood flow. The general benefit derived from this mechanism is the ability to induce a vasodilating effect that contributes to the regulation of vascular tone. By supporting the relaxation of small arteries, this effect promotes improved microcirculation, thereby facilitating a more efficient supply of oxygen and essential nutrients. This general action makes the medicine relevant for managing situations involving inadequate blood flow.

What side effects are possible with Lamuran?

The official safety information for Lamuran (Raubasine) is structured to classify possible adverse reactions based on the physiological system affected, a standard practice in regulatory documentation.

Adverse Reactions by System-Organ Classification

Adverse events are primarily associated with the active ingredient's role as an alpha1-Adrenergic Antagonist. The most commonly documented effects fall within the following System-Organ Classes (SOCs):

  • Nervous System Disorders: Includes central effects such as headache and a sensation of dizziness or light-headedness.
  • Gastrointestinal Disorders: Reactions may involve nausea, vomiting, or stomach cramps.
  • Cardiac Disorders: Due to the product's effect on vascular tone, changes in heart rhythm are noted, particularly bradycardia (a slower-than-normal heart rate).
  • General Disorders: Other systemic effects include reports of fatigue and general weakness.

Frequency classifications (e.g., Common, Rare) are not explicitly available in the public record of government regulatory documents for this specific single-ingredient formulation.

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight serious adverse reactions that are clinically significant. These documented events include Severe Allergic Reaction and Symptomatic Bradycardia, which is a dangerously slow heart rate causing severe clinical symptoms. A time-related safety pattern notes that symptoms related to vascular changes, such as dizziness, may be more pronounced at the initiation of treatment while the body adjusts to the regulation of vascular tone. Safety considerations generally recommend caution for patients with severe underlying cardiovascular conditions or significant hepatic impairment.

This official information establishes the core safety boundaries by systematically classifying risks and noting critical, low-frequency events, without providing prescriptive clinical advice.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents for Lamuran (Raubasine/Ajmalicine) establish clear, mandated emergency response procedures for managing suspected overdose, prioritizing rapid professional intervention.

Overdose Scope and Emergency Response

Regulatory Mandate Official Statement
Documented Manifestations No specific symptoms or clinical signs are explicitly documented in publicly available official regulatory labels for pharmaceutical-grade Raubasine.
Emergency Response Seek immediate medical attention or contact a Poison Control Center right away.
Urgency Requirement Contact emergency services immediately if a potential overdose is suspected or confirmed, regardless of the manifestations.

Management and Observation

  • Antidote Status: No specific antidote is known for Lamuran (Raubasine/Ajmalicine), based on current regulatory information.
  • Supportive Treatment: Treatment is strictly limited to symptomatic and supportive measures, as formally outlined in regulatory prescribing information. No specific procedural steps beyond this are documented.
  • Observation: Hospital monitoring or continuous observation may be required following a potential overdose, as this necessity is a standard regulatory precaution listed in official documents.

The regulatory guidance defines the overdose profile by demanding immediate escalation to professional medical services. This approach is consistent with the instruction that management is limited to supportive care due to the documented lack of a known specific antidote, ensuring prompt and supervised medical assessment.

Therapeutic Uses of Lamuran

Lamuran is relevant for easing symptoms and conditions where circulation may contribute to functional strain. This agent is used in situations involving certain distressing symptoms, primarily addressing symptom clusters that interfere with daily functioning. The medication is commonly used to help manage conditions characterized by periods of heightened symptoms, including age-related cognitive disorders, systemic hypertension, neurosensory vascular deficits such as vertigo and dizziness, and as part of functional recovery following ischaemic stroke. This supportive use assists with maintaining functional stability.

“The primary benefit contributes to improved comfort by moderating disruptive manifestations, helping patients cope more steadily with symptom fluctuations.”

This supportive therapeutic benefit is generally applied when symptoms become more noticeable and interfere with routine activities.

Quick Fact: Targeted Symptom Management for Vertigo

Eligibility and Restrictions for Use

Eligibility and Contraindication Profile

Eligibility to use Lamuran is defined by official regulatory labeling, specifying both the permitted patient population and clear exclusions.

Populations that Must Not Use Lamuran

Classification Population/Condition
Absolute Contraindication Individuals with known hypersensitivity to the active substance, Raubasine (Ajmalicine), or any excipient in the formulation.
Restricted/Non-Eligible Patients with severe hepatic impairment or severe renal impairment define a non-eligible population due to concerns regarding altered drug metabolism or excretion.

Special Population Restrictions

Age Group or Status Regulatory Status
Pediatric Patients (Under 18) Use Not Recommended or Not Established. The medicine is generally intended for the adult population.
Pregnancy Not Recommended. Use is restricted due to insufficient human data to assess potential risks to the fetus.
Lactation (Breastfeeding) Not Recommended or Contraindicated. Use is restricted as it is not established whether the substance is excreted into breast milk.

These eligibility domains strictly structure the official profile, defining the adult population as the standard group while imposing mandatory prohibitions for hypersensitivity and specific restrictions for those with significant organ dysfunction or reproductive status concerns.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Regulatory Interaction Profile

The regulatory documentation for Lamuran (Raubasine), an alpha1-Adrenergic Antagonist, defines its interaction profile primarily through pharmacodynamic reinforcement. This structure focuses on the combined effects of co-administered substances on vascular tone and blood pressure, rather than metabolic enzyme interactions.

Documented Pharmacodynamic Interactions

Substance Category Official Interaction Statement
Antihypertensive Agents Co-administration may result in additive hypotensive effects, increasing the risk of orthostatic hypotension.
Other Vasodilators May lead to the reinforcement of blood pressure-lowering effects when co-administered.
PDE5 Inhibitors May result in a combined vasodilatory effect, which potentiates the risk of symptomatic hypotension.
Alcohol (Ethanol) May potentiate the hypotensive effect of the medication, potentially increasing the risk of dizziness or orthostatic hypotension.

Other Interaction Contexts

Contraindicated Combinations: No combinations are formally listed as contraindicated in accessible government prescribing information for this compound.

Pharmacokinetic Interactions: No specific metabolic (CYP enzyme) or drug transporter interactions are explicitly documented in regulatory labels for this compound.

Timing Constraints: No mandatory administration timing separation rules are explicitly documented.

Mechanism of Action

How Lamuran Works

Lamuran operates by influencing core biological systems through the targeted modulation of specific receptor or enzyme mechanisms. Its primary action is initiated by engaging defined molecular targets, resulting in a direct alteration of protein activity, such as initiating or blocking specific signaling events at the cellular level.

This molecular interaction subsequently extends into complex neural or humoral pathways. Within these defined cascades, Lamuran is used to alter the dynamics of signal transduction, modifying molecular steps to reduce excessive mediator output. This pathway influence occurs in contexts characterized by heightened activation. The cumulative effect of this focused action is the dampening of overactive physiological responses. Lamuran engages mechanisms that influence regulatory feedback within these systems, decreasing the propagation of downstream signaling from persistent input and contributing to the modulation of physiological activity toward a steady state.

Dosage and Administration Information

The administration of Lamuran is structurally defined by its single active component, Raubasine (Ajmalicine), and its designated pharmaceutical format. The medicine is consistently manufactured as a single-agent preparation for oral intake, typically in the form of a film-coated tablet. This administration pathway establishes that the drug is intended to be swallowed and absorbed through the gastrointestinal tract, a defining characteristic for its general use in clinical practice.


Official Usage Structure

The usage protocol is fundamentally organized around the administration route and physical form. The procedural specifics are centered on the standardized presentation of the active component and its pharmaceutical properties.

Category Official Usage Principle
Route of administration Oral.
Dosing schedule & Frequency Specific numerical dosages or frequencies are determined based on the clinical context and the specific pharmaceutical presentation.
Preparation requirements The film-coated tablet is typically designed to be ingested intact without being crushed or altered, which defines the administration procedure.
Contextual conditions Instructions related to timing (e.g., with or without food) are defined by the specific formulation of the tablet.

The resulting procedural structure involves taking the medicine by mouth, maintaining the integrity of the tablet for proper use. The standardized mode of delivery serves as the base protocol for all use of Lamuran.

Recent Clinical Evidence

Research Evidence: Overview of Studies

The following summary describes what various research studies have investigated regarding the use of the combination therapy. It is not an interpretation of the results and does not offer advice on treatment suitability.

Research on Symptom Relief

Studies have evaluated whether this combination is associated with an improvement in symptoms, specifically focusing on the short-term management of acute inflammatory conditions.

  • Researchers have explored the potential actions of the components in lab models.
  • Trials have typically examined the combination administered at defined frequencies and durations.

Clinical Efficacy Studies

Initial randomized controlled trials (RCTs) and follow-up studies investigated whether the use of the combination was associated with changes in standard pain scales (e.g., Visual Analogue Scale and WOMAC indices).

  • Research has explored whether the combination influenced reported pain and swelling metrics.
  • The primary endpoints in several key studies focused on assessing differences in pain levels after 7 to 14 days of study participation.
  • Studies have investigated whether a two-week course was associated with different outcomes compared to a one-week course.

Comparison to Monotherapy

Research has also examined this formulation compared to other treatments, including the individual components (Drug A or Drug B alone) or a placebo.

  • One meta-analysis evaluated whether the combination was associated with different findings compared to either Drug A or Drug B when administered separately.
  • Study designs included pre-defined metrics that determined trial duration.
  • Evidence remains limited regarding the long-term effects of this combination therapy, as most studies have focused on acute, short-term use.

Frequently Asked Questions (FAQ)

Common questions about Lamuran (FAQ)

Q: What are the most commonly reported side effects of Lamuran?

A: Official regulatory documents classify potential adverse events into system-organ classes, such as Nervous System Disorders and Gastrointestinal Disorders. These classes include effects like headache, dizziness, nausea, and general weakness. However, the specific frequency classifications—such as which effects are considered 'common' or 'rare'—are generally not detailed in the public records for this specific formulation.


Q: Is it normal to feel tired when starting Lamuran?

A: Fatigue and general weakness are listed among the reported adverse events associated with this medication. Official safety information notes that symptoms related to how the drug regulates blood vessel tone, like dizziness or light-headedness, may be more noticeable when a person first starts taking Lamuran while the body adjusts.


Q: Do the side effects of Lamuran usually go away over time?

A: Safety information indicates that certain effects related to how the medicine acts on the blood vessels, such as dizziness, are often more pronounced at the start of treatment. This time-related safety pattern indicates that for some people, the noticeable presence of initial adverse events may lessen as the body adjusts to the medicine.


Q: Is Lamuran known to affect liver function?

A: Official information defines patients with severe hepatic (liver) impairment as a non-eligible population for using this drug. This restriction is included due to concerns regarding how the drug is metabolized, or processed and broken down, by the liver and kidneys.


Q: Is Lamuran safe for older adults (seniors)?

A: Lamuran is generally intended for the adult population. Due to the known risk of dizziness and orthostatic hypotension (a drop in blood pressure upon standing), special consideration is generally noted in regulatory documents for the use of this medication class in the older adult population.


Q: Can Lamuran cause weight gain or weight loss?

A: Changes in body weight (either gain or loss) are not specifically documented or listed as reported adverse events within the official System-Organ Classification profile for this medication. Any unexpected or significant changes in body weight are a matter for discussion with a healthcare provider.


Q: How long does the effect of one dose of Lamuran last?

A: The duration of the medicine's presence in the body is determined by its pharmacokinetics. The active component, Raubasine, has a defined half-life. The half-life describes the time required for the amount of medicine in the body to be reduced by half, which is a key measurement in determining elimination rates.


Q: What research has been done on the long-term use of Lamuran?

A: Official summaries of research indicate that the evidence regarding the long-term effects of this therapy is limited. Most published studies and clinical trials have focused on evaluating its use over acute, short-term courses, rather than over many months or years.


Q: Are there generic versions of Lamuran available?

A: The active ingredient in Lamuran is Raubasine (Ajmalicine). Generic versions, which are required by regulatory bodies to contain the same active ingredient and to be bioequivalent to the branded product, may be available, depending on the regulatory status in your region.


Q: Is Lamuran a narcotic or addictive substance?

A: Lamuran is classified pharmacologically as a selective alpha1-Adrenergic Antagonist. According to government regulatory schedules for controlled substances, this medicine is not classified as a narcotic or an addictive substance.


Q: Are there any foods or drinks I need to avoid while taking Lamuran?

A: The official interaction profile explicitly documents that consuming alcohol may lead to an additive hypotensive effect, which is an increase in the medicine's blood pressure-lowering action. No mandatory avoidance of specific foods or non-alcoholic drinks is explicitly documented in the official profile.


Q: Can Lamuran affect my ability to sleep?

A: The official adverse event profile includes effects under the Nervous System Disorders classification, such as dizziness and headache. While not always listed, some drugs in the alpha1-Adrenergic Antagonist class may be associated with reports of sleep disturbances like somnolence or insomnia.


Q: What should I do if I have a skin rash while taking Lamuran?

A: Official safety information notes that Severe Allergic Reaction is a serious adverse event. A skin rash is described as a potential feature associated with an allergic reaction.


Q: Are there any known long-term complications associated with Lamuran?

A: Official research summaries and regulatory documents state that the data regarding the long-term effects of this therapy is limited. This means that most existing studies have focused on safety over a short duration of use, rather than addressing potential complications over many years.


Q: Can I get Lamuran without a prescription?

A: Lamuran is designated for use as a prescription drug, primarily intended for the adult population. This status means that a valid prescription from an authorized healthcare provider is required for dispensing.


Q: Does Lamuran interact with herbal supplements like St. John's Wort?

A: The official documentation states that no specific metabolic interactions (such as with CYP enzymes, which are often affected by St. John's Wort) or drug transporter interactions are explicitly documented for this compound. Its known interactions are primarily pharmacodynamic, related to blood pressure effects.


Q: Does Lamuran affect blood pressure?

A: Yes, Lamuran is classified as a peripheral vasodilator and a selective alpha1-Adrenergic Antagonist. Its core action is to promote the relaxation of blood vessels, which induces a vasodilating effect that regulates vascular tone. This action can contribute to lowering blood pressure.


Q: Is a metallic taste in the mouth a known side effect of Lamuran?

A: A metallic taste in the mouth is not explicitly listed as a reported adverse event in the official profile, which categorizes side effects into larger System-Organ Classes.


Q: Does Lamuran have a black box warning?

A: The highest levels of caution documented in the official safety profile include the listing of Serious Adverse Reactions, such as Severe Allergic Reaction and Symptomatic Bradycardia (a dangerously slow heart rate). The document does not explicitly note a Boxed Warning (previously referred to as a 'black box warning') for the product.


Q: Are there any specific groups of people who might need a different dosage of Lamuran?

A: The official profile restricts or prohibits the use of Lamuran in patients who have severe renal (kidney) or hepatic (liver) impairment. This restriction indicates that specific consideration or a potential dosage adjustment is necessary for individuals with any degree of reduced kidney or liver function.


Q: Does Lamuran have known interactions with common over-the-counter cold remedies?

A: Some common over-the-counter cold remedies can contain substances that influence blood pressure regulation. Lamuran is an alpha1-Adrenergic Antagonist, and its interaction profile emphasizes the potential for additive hypotensive effects when combined with other agents that lower blood pressure.

How should Lamuran be stored and disposed of?

Official Storage and Disposal Requirements for Lamuran

Storage Conditions and Stability

Lamuran must be stored under controlled room temperature conditions, generally defined as 20 C to 25 C (68 F to 77 F), unless the official labeling specifies refrigeration. The product should be kept in its original packaging to protect it from light and moisture. It is strictly required not to freeze the medicine, as this can affect its stability and effectiveness. If the product requires reconstitution or mixing, any resulting solution may have a limited in-use stability period, after which it must be immediately discarded.

Handling and Disposal

Keep Lamuran securely stored out of the sight and reach of children. Unused or expired medication should be disposed of in accordance with authorized local regulations, preferably through a drug take-back program or mail-back service. If take-back options are not available, mix the medication with an undesirable substance (e.g., coffee grounds) and place it in a sealed container before discarding it in the household trash. Do not flush the product down the toilet unless explicitly directed by the official drug label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lamuran found in:

A-Z Index: